admin

NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced enrollment of 40 patients and commencement of its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum. The study is being […]

by

NEW YORK, March 07, 2017 — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced enrollment of 40 patients and commencement of its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum. The study is being conducted by […]

NEW YORK – (Uptick Newswire – March 8, 2017) – Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome […]

Medical Marijuana Inc (OTCMKTS:MJNA) recently saw a drop back to $0.10 support levels after the stock failed to take out $0.268 previous highs of November. MJNA remains an Investors favorite and a staple among the top most traded stocks on the entire exchange especially when pot stocks heat up. MJNA is one of the original pot […]

LONDON, March 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Scott Giacobello as Chief Financial Officer on 6 March 2017. Reporting to GW’s Chief Executive Officer […]

Final data collection for primary outcome measure is estimated to complete in April 2017, with the full study estimated to complete in June 2017. “Successfully enrolling patients in this IBS clinical trial, which marks the first advancement in cannabinoid research for treatment of IBS in medical history, is an exciting new milestone for AXIM’s clinical […]

LONDON, March 02, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, 8 […]

LONDON, March 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Scott Giacobello as Chief Financial Officer on 6 March 2017. Reporting to GW’s Chief Executive Officer […]

NEW YORK, March 07, 2017 — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced enrollment of 40 patients and commencement of its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum. The study is being conducted by […]

LONDON, March 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH), (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Scott Giacobello as Chief Financial Officer on 6 March 2017. Reporting to GW’s Chief Executive Officer […]

LONDON, March 02, 2017 — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, 8 March, 2017 […]

In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site. Medscape uses cookies to customize the site based on the information we collect at registration. The cookies contain no personally identifiable information and have no effect once you leave the Medscape site. … read more at: http://www.medscape.com/viewarticle/873167